Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term certolizumab pegol maintenance in Crohn's disease (post C87042)
2006-001729-24Phase 3Completed
- Sponsor
- UCB
- Start
- Sep 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoints: Long-term safety of certolizumab pegol and Maintenance of clinical response in Crohn's disease. Started Sep 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2006-001729-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001729-24.